Table 2.
Active EAE induction with hPLP peptides
| HLA Tg mice | Immunization | Incidence | Maximal clinical severity | Day of onset |
|---|---|---|---|---|
| DRB1*1501 | hPLP30-51 | 0/4 | -- | -- |
| hPLP30-51* | 0/4 | -- | -- | |
| hPLP41-60 | 0/4 | -- | -- | |
| hPLP41-60* | 0/4 | -- | -- | |
| hPLP95-116* | 0/4 | -- | -- | |
| hPLP139-151* | 0/3 | -- | -- | |
| hPLP175-194 | 0/3 | -- | -- | |
| hPLP175-194* | 0/4 | -- | -- | |
| hPLP185-206 | 0/3 | -- | -- | |
| hPLP185-206* | 0/9 | -- | -- | |
| hPLP195-216 | 0/3 | -- | -- | |
| hPLP195-216* | 0/4 | -- | -- | |
| hPLP206-226 | 0/3 | -- | -- | |
| hPLP206-226* | 0/3 | -- | -- | |
| hPLP257-276* | 0/3 | -- | -- | |
| hΔPLP* | 0/4 | -- | -- | |
| DQB1*0602 | hPLP30-51 | 0/2 | -- | -- |
| hPLP30-51* | 0/4 | -- | -- | |
| hPLP84-102 | 0/2 | -- | -- | |
| hPLP139-151* | 6/15 | 1,2,1,1,1,1 | 13,15,16,13,14,14 | |
| hPLP175-194* | 5/9 | 2,3,1,3,1 | 13,14,15,20, 21 | |
| h175-183S-194* | 0/5 | -- | -- | |
| hPLP206-226 | 0/3 | -- | -- | |
| hPLP206-226* | 0/4 | -- | -- | |
| hPLP215-235 | 0/4 | -- | -- | |
| hPLP215-235* | 0/4 | -- | -- | |
| hPLP257-276 | 0/8 | -- | -- | |
| hPLP257-276* | 0/4 | -- | -- | |
| hΔPLP*, ** | 0/8 | -- | -- | |
Mice were injected with 200 μg of PLP peptide or hΔPLP, and received 300 ng PT immediately and after 48 h (protocol 1)
*, Mice received a boost after a week (protocol 2)
**, The Cys to Ser replacements in the hΔPLP abrogated the encephalitogeinc potential of epitopes, as shown here for PLP175-183Cys/Ser-194 mutated peptide and detailed in Results